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1530Objective: Our objective was to elucidate long-term clinical and functional effects of intramyocardial stem cell
transplant and to identify patients who will show sustained benefit.
Methods: Long-term outcomes of 35 patients after intramyocardial CD133þbone marrow stem cell transplant
during coronary artery bypass grafting were compared with those of a control group of 20 patients after coronary
artery bypass grafting alone. Clinical effects were assessed with the New York Heart Association classification
system and the Minnesota Living With Heart Failure questionnaire. Electrocardiography, 24-hour Holter
monitoring, echocardiography, myocardial perfusion scanning, magnetic resonance imaging, and computed
tomography were performed. Logistic regression analyses were used to identify prognostic factors for improve-
ment in long-term left ventricular ejection fraction after stem cell treatment.
Results: The stem cell group revealed similar New York Heart Association and life quality scores to the control
group. Myocardial perfusion score at the area of risk was significantly increased in the stem cell group after
36-month follow-up (P ¼ .024 vs control). Multivariate logistic regression analysis revealed a 44-fold higher
probability of at least 5% improvement in left ventricular ejection fraction for patients with preoperative left
ventricular ejection fraction not greater than 40% than for patients with preoperative ejection fraction greater
than 40% (P ¼ .018). Furthermore, patients operated on between 7 and 12 weeks after myocardial infarction
had a 56-fold higher chance of at least 5% improvement in left ventricular ejection fraction than patients treated
later than 12 weeks after infarction (P ¼ .023).
Conclusions: Intramyocardial stem cell therapy was safe but lacked significant lasting benefits beyond 6months
in our study cohort with a limited number of patients. Preoperative left ventricular ejection fraction and time
since myocardial infarction may be critical parameters for selection of patients who can benefit most from
intramyocardial stem cell treatment during coronary artery bypass grafting. (J Thorac Cardiovasc Surg
2011;142:1530-9)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surnumerous experimental and clinical investigations. Various
stem cell lineages and delivery routes have been instituted,
with encouraging results that have often been associated
with improvements in left ventricular function and perfu-
sion.1-8 Among the cell lineages used, bone marrow stem
cells (BMSCs) have been shown to contribute to functional
myocardial recovery through induction of angiogenesis,
limitation of apoptosis, and other positive effects on
cardiomyocyte salvage pathways.4,9-13 Several clinical
studies with BMSCs, including those from our group,
have demonstrated functional benefits of myocardial
treatment with stem cells during short- or medium-term
follow-up.14,15
In addition to application routes such as intracoronary,
intraventricular, and transventricular approaches, patients
undergoing coronary artery bypass grafting (CABG) have
been preferentially included in clinical trials of stem cell
treatment. The main reason behind this approach is the
unlimited access of the cardiac surgeon to the site of the
infarcted myocardium, which enables cells to be appliedgery c December 2011
Abbreviations and Acronyms
ANCOVA ¼ analysis of covariance
BMSC ¼ bone marrow stem cell
CABG ¼ coronary artery bypass grafting
LVEDD ¼ left ventricular end-diastolic
diameter
LVEDV ¼ left ventricular end-diastolic volume
LVEF ¼ left ventricular ejection fraction
MLHFQ ¼ Minnesota Living With Heart
Failure Questionnaire
MRI ¼ magnetic resonance imaging
NYHA ¼ New York Heart Association
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Mto the target region by direct intramyocardial injection. This
strategy has significant advantages relative to intracoronary
or endomyocardial delivery methods with respect to the
precision of cellular targeting.
Since June 2001, we have used a protocol for intramyo-
cardial injection of purified CD133þBMSCs that involves
their direct application into the diseased myocardium at
the time of CABG. Medium-term follow-up results have
already been published.15,16 Although short-term safety and
functional results regarding cardiac stemcell treatment are en-
couraging, long-term safety and efficacy data are still lacking
and greatly needed. First, we wanted to rule out possible side
effects of stemcell therapy on the basis of longer-term follow-
up data.17-19 Second, we found it necessary to examine the
efficacy of this therapeutic modality as a sustained clinical
and functional advantage. Finally, we aimed to identify the
specific patient groups showing the most benefit from
autologous intramyocardial BMSC transplant concomitant
with CABG. We here provide follow-up out to 9 years with
nearly complete results of the clinical assessment of both
the stem cell and control groups. Furthermore, functional
investigations on 20 stem cell–treated patients are presented
together with data from a control group of 15 patients who
also underwent long-term follow-up investigations.MATERIALS AND METHODS
Patient characteristics are listed in Table 1. The study was approved by
the institutional review board and ethics committee at the University of Ro-
stock. Informed consent was obtained from each patient before enrollment.
Inclusion criteria were as follows: (1) history of myocardial infarction at
least 14 days before admission, (2) indication for bypass grafting on coro-
nary arteries other than the infarct vessel, and (3) distinct area of akinetic
left ventricular myocardium corresponding with the infarct localization.
Exclusion criteria were as follows: (1) debilitating chronic disease
(malignancy or terminal renal failure), (2) emergency operation, (3) con-
comitant valve surgery, and (4) history of malignant ventricular arrhyth-
mia. To accelerate recruitment, the inclusion criteria were slightly
modified during the phase II trial as follows: (1) patients needing concom-
itant mitral valve repair for regurgitation were included, and (2) in the
absence of a distinctly akinetic areawithin the left ventricular myocardium,The Journal of Thoracic and Cara globally reduced left ventricular ejection fraction (LVEF) was accepted.
We did, however, exclude patients who underwent concomitant valve sur-
gery from our long-term analysis. None of the patients in this evaluation
had significant valvular pathology necessitating valvular intervention
preoperatively or during the follow-up. Once it was determined that the
main inclusion criteria had been met, enrollment was discussed with the
patient and informed consent obtained. Next, the patient was referred for
myocardial perfusion scintigraphy, Holter electrocardiography, and,
recently, cardiac magnetic resonance imaging (MRI) as well. In the con-
trolled study arm, random patient allocation to the control or treatment
group was performed as described in Appendix E1.
Stem cell preparation and the technique of stem cell transplant with con-
comitant CABG have already been described in our previous reports15
(Appendix E2). In brief, autologous CD133þ BMSCs were isolated from
bone marrow aspirate before CABG with the Miltenyi Biotec CliniMACS
system (Miltenyi Biotec Inc, Auburn, Calif). A mean of 6.0 3 106 cells
(range, 1.0–10.0 3 106 cells) were injected into the border zone of the
infarcted myocardium during on-pump CABG under cardioplegic arrest.
Enrollment in the safety trial began in June 2001 and was completed in
February 2003. The efficacy study began in May 2003 and was completed
in February 2005. Long-term follow-up investigations were finalized in
April 2010.Long-Term Follow-up Investigations (Table E1)
Minnesota Living With Heart Failure Questionnaire.
Patient self-assessments were obtained with the Minnesota Living With
Heart Failure Questionnaire (MLHFQ), a widely accepted disease-
specific tool for the assessment of patients with heart failure in which
a higher score indicates greater negative impact of the disease.20 MLHFQ
scores were not available preoperatively. The questionnaires were either
sent to patients by conventional mail or filled out by the patients at the
time of the inpatient long-term follow-up investigations.
New York Heart Association functional classification.
The NewYork Heart Association (NYHA) functional class was determined
preoperatively and when patients were admitted for a long-term follow-up
visit to the clinic or by mail correspondence according to widely accepted
guidelines. The scores were compared between the stem cell and control
groups in the long-term follow-up.
Transthoracic echocardiography. Transthoracic echocardiog-
raphy was performed to measure global left ventricular contractility and
dimensions. These measurements were conducted by 2 experienced echo-
cardiographers who were blinded to the presence and region of stem cell
injection. The LVEF, left ventricular end-diastolic diameter (LVEDD),
and left ventricular end-diastolic volume (LVEDV) were determined. After
the preoperative baseline evaluation, the patients underwent transthoracic
echocardiography at 6 postoperative months, at 18 postoperative months,
and at 65 21 and 62 9 postoperativemonths in the stem cell and control
groups, respectively.
Myocardial perfusion scan. To determine myocardial perfusion
in the area of risk, single-photon emission computed tomography (CT)
was performed at rest. A bolus of 100-MBq thallous chloride Tl-201 was
injected intravenously, and scans were completed 5 minutes after injection
with a 3-head gamma camera (Irix; Philips Nederland BV Medical Sys-
tems, Eindhoven, The Netherlands) in combination with a nonuniform at-
tenuation correction. Images were assessed by quantitative measurements
of the activity in the area at risk, the infarction zone, which was expressed
as the ratio of postoperative to preoperative activity (arbitrarily set as 1.0).
Myocardial perfusion scores were determined during the follow-up in all
patients in whom stem cell injection had been performed, focusing on
the peri-infarction area. The scores after 12 months and 36 months of
follow-up were compared between the groups.
Twenty-four–hour Holter monitoring. Twenty-four–hour
Holter monitoring was used for each patient to detect any sustaineddiovascular Surgery c Volume 142, Number 6 1531
TABLE 1. Baseline data of patients
Parameter Control group Stem cell group P value
Age (y, mean  SD) 63.5  8.4 63.7  9.6 .66
Sex (male/female) 16:4 30:5 .71
Infarct time (wk, median
and range)
7.5 (2–830) 7.9 (2–1215) .91
New York Heart Association functional class (No.)
II 13 (65%) 22 (62.9%)
III 7 (35%) 13 (37.1%)
Coronary artery stenosis (no.)
Left main 7 (35%) 14 (40%) .75
Left anterior descending 20 (100%) 32 (91%) .49
Left circumflex 17 (85%) 25 (71%) .45
Right 18 (90%) 30 (86%) .99
Target area for cell injection (no.)
Anterior NA 14 (40%)
Posterior NA 19 (54%)
Apex NA 9 (26%)
Holter findings (no.)
Relevant ventricular
extrasystole
1 0
Atrial fibrillation 0 0
Intraoperative data
No. of bypasses
(mean  SD)
3.6  0.8 3.5  0.9 .98
Left internal thoracic
artery use (no.)
20 (100%) 29 (83%) .07
Cell dose (3106 cells,
median and range)
NA 6.0 (1.0–10.0)
No. of injections NA 10
Postoperative data
Need for inotropes (no.) 12 (60%) 23 (66%) .77
Mechanical ventilation
(h, mean  SD)
6.0  2.0 6.1  2.4 .64
Creatine kinase (IU,
median and range)
507 (195–1166) 466 (155–3698) .79
Creatine kinase
isoenzyme MB (IU,
median and range)
28 (12–43) 25 (12–85) .61
Ventricular extrasystole
(% of all QRS,
mean  SD)
0.8%  0.01% 0.5%  0.009% .21
Hospital stay
(d, mean  SD)
12  2 14  3 .18
NA, Not applicable.
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Marrhythmias both preoperatively and postoperatively during the follow-up
visits at 3 months, 6 months, 18 months, and long-term follow-up for
up to 5 postoperative years. The Lown classification was used for
quantification.
MRI and CT. Cardiac MRI and CT were included in the long-term
investigations to provide both functional and morphologic data.
Gadolinium-enhanced MRI was performed within long-term follow-up
investigations to assess global left ventricular function and to detect the1532 The Journal of Thoracic and Cardiovascular Surpresence of tissue changes. The patients were examined in the supine po-
sition with a 1.5-T system (MagnetomAvanto; SiemensMedical Solutions,
Erlangen, Germany), and a phased-array cardiac coil was used for signal
reception. All images were obtained during repeated breath-holding inter-
vals and were electrocardiographically gated. MRI analysis was performed
in a semiautomated fashion separately by observers who were unaware of
patient group identity or timing of the scanning. LVEF at rest was
calculated from theMRI cine short-axis views with commercially available
software (Syngo Argus; Siemens Medical Solutions). In addition, the radi-
ologists were asked to indicate the presence, location, and degree of any
myocardial inflammation, scar, or tumor formation.
When the first reports about tissue changes after cell treatment were
noted,19 the diagnostic long-term evaluation by cardiac CT was started
for all treated patients to detect possible intramyocardial calcification
caused by BMSC injections. This evaluation was performed only once
during the follow-up as part of the long-term investigations.
The images were obtained with a 32-slice native CT scan (Toshiba
Aquilion 32; Toshiba Medical Systems Corp, Tochigi, Japan) during 2
breath-holding intervals, and these images were electrocardiographically
gated. The myocardiumwas scanned in sections of 5-mmwidth. The Vitrea
2 workstation (Vital Images, Inc, Minnetonka, Minn) was used for the as-
sessment of myocardial calcifications. The blinded radiologists were asked
to indicate the presence, location, and degree of any myocardial calcifica-
tion and tissue changes.
Statistical Analysis
All data were stored and analyzed with the SPSS software package (ver-
sion 15.0; SPSS Inc, an IBM Company, Chicago, Ill). Descriptive statistics
were computed for variables of interest. The statistics computed included
mean and SD for continuous variables and frequencies and relative fre-
quencies for categoric factors. Results are presented as mean  SD.
With regard to possible baseline effects, the 2-sided hypothesis for the
continuous primary variable of LVEF at different postoperative time points
was provided by analysis of covariance (ANCOVA) with adjustment for
baseline LVEF. Furthermore, we applied the generalized linear model
repeated measures procedure for statistical analysis of the data to test the
null hypotheses about the effects of both the between-subject factor (ther-
apy group) and the within-subject factor (time). In dependence of distribu-
tions, the paired t test or the Wilcoxon test was used for the comparisons
within the groups between 2 time points. For comparisons between more
than 2 times, we performed repeated measures analysis of variance or
nonparametric Friedman test. Comparisons between the study groups for
categoric variables were done with the c2 test or Fisher’s Exact test.
Logistic regression analyses were done to identify independent prog-
nostic factors for an improvement in LVEF of at least 5%. Variables that
tended to have a 1-dimensional effect on improvement (P<.2) were ana-
lyzed with a multivariate logistic regression model. Odds ratios and their
95% confidence intervals were calculated.
All P values resulted from 2-sided statistical tests.RESULTS
Stem Cell Group
Fifteen patients were enrolled in the initial safety and fea-
sibility trial. All but 4 patients are alive and well at the time
of submission of this report. A 75-year-old man with cere-
brovascular disease was unavailable for follow-up 9 months
after surgery. Later investigation revealed that he had died
of a stroke (no autopsy available). Three patients died at
62 postoperative months, 73 postoperative months, and 81
postoperative months. The reasons for their deaths are not
available because of the lack of autopsies.gery c December 2011
FIGURE 1. Kaplan-Meier survival curve for stem cell–treated group
(blue) and control group (red).
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to undergo either CABG and cell transplant or CABG alone.
Twenty patients in the stem cell treatment group received
a median dose of 7.2 3 106 CD133þBMSCs. One patient
was excluded because of postoperative deep sternal wound
infection and poor compliance with the follow-up examina-
tions. During the follow-up period, a 68-year-old female
patient died of an unknown cause after a follow-up of 21
months. Another woman died of an unknown cause 57
months after surgery. As of this writing, all other patients
are alive and well. Thus among the 35 patients who were
treated with stem cell injection, one was excluded from
the study and 6 deaths occurred as outlined here
(Figure 1). The follow-up duration ranged between 32 and
99 months, with a mean follow-up of 65  21 months,
and encompassed a total of 1306 patient-months.Control Group
In the control group with a total 20 patients, 2 patients
were not available for the long-term follow-up because
they decided not to attend further investigations. Three pa-
tients died during the follow-up: 2 male patients at 18 and
65 postoperative months and 1 female patient at 15 postop-
erative months (Figure 1). The male patient who died at 15
postoperative months had an echocardiographic LVEF of
24% and showed improved left ventricular performance
in the 6-month follow-up investigation with LVEF of 50
%. It was reported that he died of multiorgan failure after
sepsis. The reason for the death of the other male patientThe Journal of Thoracic and Caris unknown. The female patient had no change from the
LVEF of 37% reported at discharge. She did not undergo
further follow-up studies and had sudden cardiac death.
Follow-up time for the group ranged between 48 and 76
months, with a mean follow up of 62 9 months and a total
of 923 patient-months.
Adverse Events
In the stem cell–treated patient group, no myocardial in-
farctions or acute cardiac reinterventions were observed
during the entire follow-up period. One male had to undergo
mitral and aortic valve replacement as a result of acute bac-
terial endocarditis at 1 postoperative year. Streptococcus
boviswas isolated from blood cultures, but no colon neopla-
sia could be detected. Other than serious neglect of dental
hygiene, no risk factors for the endocarditis could be found.
The occurrence of bacterial endocarditis was considered
a major adverse cardiac event. Another male patient under-
went elective coronary angioplasty as a result of worsening
of his coronary heart disease and angina pectoris at 17 post-
operative months. With respect to noncardiac events, a 79-
year-old male patient survived a mild episode of pulmonary
embolism resulting from deep venous thrombosis of the
lower extremity during the late follow-up phase.
In the control group, 1 female patient (as mentioned pre-
viously) had sudden cardiac death, which was considered
a major adverse cardiac event. No more detailed informa-
tion could be gained about this patient. A 78-year-old
male patient survived global cardiac decompensation after
the institution of anti–congestive heart failure therapy. Alto-
gether, there was no significant difference in the frequency
of adverse events between the 2 treatment groups (Fisher’s
Exact test, P ¼ .364 between the stem cell and the control
groups for the major adverse cardiac events and P>.999
for the mild adverse events).
Minnesota Living With Heart Failure Questionnaire
The stem cell–treated patients (n ¼ 26) had an average
cumulative score of 19.9  17.3 on the MLHFQ, versus
28.4  23.3 in the control group (n ¼ 14; Figure 2). These
results indicate that patients in the stem cell treatment
group judged their quality of life with respect to their heart
failure similarly to the patients in the control group
(P¼ .19). In the analysis of the stem cell group in the safety
trial alone, we encountered a score of 15  7.9 at the long-
term follow-up, whereas the stem cell group in the efficacy
trial had a score of 23.3  22.3. The differences were still
nonsignificant.
NYHA Functional Classification
The average NYHA functional class improved in the
stem cell–treated patients (n ¼ 34) from a preoperative
value of 2.6  0.3 to 1.6  0.8 after a mean follow-up of
43 months (range, 24–69 months). The control groupdiovascular Surgery c Volume 142, Number 6 1533
FIGURE 2. Comparisons of functional outcomes. A, Minnesota LivingWith Heart Failure Questionnaire (MLHFQ) scores in the stem cell group (n¼ 26)
and the control group (n ¼ 14) at long-term follow-up. Preoperative Minnesota Living With Heart Failure Questionnaire scores of the groups were not
available. B, New York Heart Association (NYHA) functional class values in the stem cell group (n¼ 34) and the control group (n¼ 13) both preoperatively
(Pre) and at long-term follow-up (LTFU). Asterisk indicates P<.05 versus preoperative value.
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M(n¼ 13) showed a similar improvement from 2.5 0.2 pre-
operatively to 1.8  0.9 in the long-term evaluation after
a mean follow-up of 36 months (range, 21–48 months).
The improvement in the NYHA functional class was statis-
tically significant within each group when comparing the
preoperative and long-term follow-up values (Wilcoxon
test, P<.001 for stem cell group and P ¼ .025 for control
group). Figure 2 shows the change in NYHA functional
class, with a comparison of stem cell and control groups.
No statistically significant difference was observed between
the stem cell and control groups in the long-term follow-up
(ANCOVA with preoperative NYHA value as covariable,
P¼ .647). When patients in the safety trial were considered
separately, a similar estimate of NYHA functional class re-
sulted. Patients in the safety trial (n¼ 15) had improvement
from a preoperative NYHA functional class of 2.6  0.3 to
1.5  0.7 in the long-term follow-up. Similarly, patients
in the efficacy trial (n ¼ 20) had improvement in NYHA
functional class from 2.6  0.2 to 1.6  0.8 in the long-
term follow-up investigations.
Twenty-Four–Hour Holter Monitoring
In the stem cell group (n ¼ 20), the Lown class had not
changed after 41  6 months of follow-up, with preopera-
tive and long-term follow-up values of 0.9  1.0 and 1.1
 0.9, respectively (P ¼ .524). No malignant ventricular
arrhythmias or other life-threatening arrhythmias were re-
corded at any time during the entire follow-up. The Holter
evaluation in the control group (n ¼ 15) revealed a greater
difference from the preoperative Lown class after 39  5
months of follow-up, with values of 1.2  0.5 and 1.5 
0.8, respectively (P ¼ .356).
Echocardiography
Long-term follow-up echocardiography was available for
20 stem cell–treated patients and 15 patients in the control1534 The Journal of Thoracic and Cardiovascular Surgroup. The echocardiographic analyses for the stem cell–
treated patients and the control group for the long-term
evaluation are given in Table 2. In the stem cell–treated pa-
tients, the preoperative LVEF was 41.1%  8.1%, and this
value rose significantly to 49.9%  8.0% at 6 months
(paired t test, P ¼ .002). LVEF values were determined to
be 45.5% 10.2% at 18 months and 46.9% 12.1% after
a mean of 65  21 months of follow-up. In the control
group, the preoperative LVEF value of 40.5%  10.3%
rose to 43.9%  7.0% at 6 months (paired t test,
P ¼ .032), and LVEF values were 46.9%  5.8% and
45.9%  11.9% at mean follow-ups of 18 and 62  9
months, respectively (Table 2).
For the LVEF value at 6 months, we observed a statisti-
cally significant difference between the stem cell and control
groups (ANCOVA with the preoperative LVEF value as
a covariable P¼ .027) but for the long-term follow-up there
was no significant difference (ANCOVAwith preoperative
LVEF value as covariable P ¼ .802). The changes in
LVEF during the follow-up period are shown in Figure 3, A.
Because assumptions for a multivariate approach (equal-
ity of variance–covariance matrices) were proved to be false
by the Box’s M test (P ¼ .026) we performed univariate
LVEF approach of the generalized linear model repeated
measures analysis. For testing the within-subjects factor
(time) and the interaction of the within-subjects factor and
the between-subjects factor (time 3 therapy group), valid-
ity of the assumption that variance–covariance matrix was
circular was assessed by performing the test of sphericity
by Mauchly with P ¼ .005. Consequently, for testing the
within-subjects factor (time) and the interaction of the
within-subjects factor and the between-subjects factor
(time 3 therapy group), we used the Greenhouse-Geisser
modification of the F test. As a result, the time effect was
found to be significant (P ¼ .024) and the time 3 therapy
group interaction not significant (P ¼ .431). That meansgery c December 2011
TABLE 2. Echocardiographic data of patients who underwent long-term follow-up investigations
LV ejection fraction (%) LV end-diastolic volume (mm)
Control Stem cell Control Stem cell
Preoperative 40.5%  10.3% 41.1%  8.1% 58.6  5.5 55.7  5.4
6 mo 43.9%  7.0%* 49.9%  8.0%*y 56.7  5.6 53.8  7.0
18 mo 46.9%  5.8% 45.5%  10.2% 57.1  5.3 53.9  6.3
Long-term follow-up 45.8%  11.9% 46.9%  12.1% 57.1  5.3 56.6  7.3
All data are mean  SD. Long-term follow-up periods were 65  21 months and 62  9 months for the stem cell (n ¼ 20) and control (n ¼ 15) groups, respectively. LV, Left
ventricular. *P<.05 versus preoperative. yP<.05 versus control group.
Yerebakan et al Perioperative Managementthat on the one hand the hypothesis that for the whole data
set the LVEF values at all 4 time points were equal is re-
jected, and on the other hand the hypothesis that deviations
from equality over the 4 time points were the same for the 2
groups is not rejected. Consequently, the factor of group had
no independent influence on course during the whole time
period. Furthermore, we introduced contrasts among the
within-subject variable in to study the levels of the
within-subjects factor. We used the deviation contrast com-
paring a given level of time to the mean of all levels and
tested 2 hypotheses. First, averaged over the 2 groups, the
mean of the specified contrast was 0. Second, the means
of the specified contrast were the same for the 2 groups.FIGURE 3. A, Comparison of all patients from the stem cell and control group
(LTFU) with respect to left ventricular ejection fraction (LVEF) improvement
course of a subgroup of patients in both groups with a preoperative left ventri
cell group (n¼ 9) and the control group (n¼ 7). C, Comparison between the stem
fraction (LVEF) in the long-term follow-up relative to the preoperative left ventr
ventricular ejection fraction not greater than 40%. Long-term follow-ups were
group, respectively. Asterisk indicates P<.05 versus preoperative; dagger indi
The Journal of Thoracic and CarAs expected, for the first test, only for the contrast of the
difference between the time point of 6 months and the grand
mean of all 4 time points we could detect a significant in-
crease averaged over the 2 groups (P ¼ .024). Hypotheses
that the means of a specified contrast were the same for
the 2 groups were rejected only for the contrast of 6 months
versus grand mean (P ¼ .038).
For the parameter LVEDD, the generalized linear model
repeated measures analysis offered no significant differ-
ences, neither for testing the within-subjects factor (time)
and the interaction of the within-subjects factor and the
between-subjects factor (time 3 therapy group) nor be-
tween the 2 therapy groups. When only the randomizeds who underwent echocardiographic evaluation in the long-term follow-up
during the follow-up period. B, Left ventricular ejection fraction (LVEF)
cular ejection fraction not more than 40% is compared between the stem
cell and control groups of the improvement in the left ventricular ejection
icular ejection fraction for the subgroup of patients with a preoperative left
65  21 months and 62  9 months for the stem cell group and the control
cates P<.05 versus control group.
diovascular Surgery c Volume 142, Number 6 1535
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Mpatients (stem cell n ¼ 12, control n ¼ 15) were analyzed,
we could confirm similar results. Only for the contrast of
the difference between the time point of 6 months and the
grand mean of all 4 time points did we detect a significant
increase averaged over 2 groups (P ¼ .007). Hypotheses
that the means of a specified contrast were the same for
the 2 groups were rejected only for the contrast of 6 months
versus the grand mean (P ¼ .011).
We conducted further subgroup analysis of patients who
had a preoperative LVEF no greater than 40%. Compari-
sons were realized by nonparametric tests to take into ac-
count the very small number of patients. Within this
subgroup, the stem cell group patients (n ¼ 9) had signifi-
cant improvements from their preoperative mean LVEF of
33.0%  5.4% to 50.6%  9.4%, 45.6%  11.8%, and
52.1% 14.8% at 6 months, 18 months, and long-term fol-
low-up, respectively (Friedman test P ¼ .001). In compari-
son, the control group (n ¼ 7) showed a nonsignificant
improvement of the LVEF from 32.6%  9.7% preopera-
tively to 37.6%  6.9%, 46.0%  7.7%, and 39.3% 
14.0% at 6 months, 18 months, and long-term follow-up.
Within this subgroup of patients with lower preoperative
LVEF, we detected significant differences at 6 months of
follow-up exclusively between the stem cell group and the
control group (Mann-Whitney test P ¼ .012 for LVEF,
P ¼ .016 for LVEDD, 52.7  7.4 mm and 60.3  3.1 mm
for the stem cell and control groups respectively). The
LVEF differences in this subgroup of patients in the stem
cell and control groups are shown in Figure 3, B and C.
Univariate logistic regression analysis identified the pre-
operative LVEF, elapsed time after myocardial infarction,
and number of bypass grafts as significant factors to include
in a multivariate logistic regression analysis (Table E2).
Multivariate logistic regression revealed that patients with
a preoperative LVEF not greater than 40% had a 44-fold
higher chance of showing at least 5% LVEF improvement
in the long-term follow-up (P ¼ .018). Moreover, when pa-
tients were treated between 7 and 12 weeks after myocardial
infarction, they had a 56-fold higher chance of at least 5%
LVEF improvement relative to those who were treated be-
yond 12 weeks after myocardial infarction (P ¼ .023).
The number of bypass grafts constructed did not signifi-
cantly influence functional improvement (Table E3).
Myocardial Perfusion Scan
Myocardial perfusion scans were available at mean
follow-ups of 12  5 and 36  6 months from 24 stem
cell-treated patients and 11 patients from the control group.
The stem cell–treated patients did not score lower than the
preoperative baseline value of 1.0 at 12 and 36 months, with
values of 1.04  0.15 and 1.13  0.25, respectively,
whereas the patients in the control group did not show
any differences relative to the preoperative levels with re-
spect to the perfusion in the area of interest, with scores1536 The Journal of Thoracic and Cardiovascular Surof 0.98  0.13 and 0.95  0.13 after 12 and 36 months,
respectively. The scores in both groups compared after
a mean follow-up of 36 months revealed a significantly
better perfusion score in the stem cell group (P ¼ .024).
Figure E1 is a representative image of myocardial perfu-
sion in the area of interest in a patient of the stem cell group
taken during follow-up at 3 years.
Magnetic Resonance Imaging
Functional data are available for 18 stem cell–treated pa-
tients (n ¼ 8 from the safety trial, n ¼ 10 from the efficacy
trial) and 7 patients in the control group only within long-
term follow-up. Preoperative data were not available. No
adverse tissue changes were detected. The mean LVEF
values detected by MRI were 52.8%  13.8% in the
stem cell–treated patients after a mean follow-up of 41 
4 months and 47.3%  11.5% in the control group after
a mean follow-up of 39  3 months. The difference in the
LVEF was not statistically significant (P ¼ .304). Stem
cell–treated patients had LVEDV index value of 68.1 
14.9 mL/m2, whereas in the control group this value was
90.5  14.3 mL/m2. The left ventricular end-systolic vol-
ume index values were 31.6  16.3 mL/m2 and 53.7 
8.3 mL/m2 for stem cell and control groups, respectively.
The LVEDV and left ventricular end-systolic volume indi-
ces were significantly lower in the stem cell–treated patients
than in the control group (P ¼ .017 for both parameters).
Cardiac CT
Cardiac CTwas available for 15 patients in the stem cell
group after 49  9 months of follow-up. In the control
group, 7 patients underwent cardiac CTafter 43 5 months
of follow-up. In the long-term follow-up investigations, no
adverse tissue changes, such as intramyocardial calcifica-
tion or tumor formation were, recorded in the stem cell–
treated patients enrolled in the phase I and phase II trials
at the sites of intramyocardial BMSC transplant or in the
control group patients from the phase II trial.
DISCUSSION
The main findings of our long-term follow-up investiga-
tions can be summarized as follows: (1) Intramyocardial au-
tologous transplant of purified CD133þBMSCs in a dose as
high as 10 3 106 cells with concomitant CABG is feasible
and safe, and it provides excellent long-term survival and
safety according to our follow-up results out to 9 postoper-
ative years. The results show limited and temporary true
functional benefit for the myocardial performance, as deter-
mined by echocardiography in the long-term evaluation of
this small cohort of patients. With regard to possible side ef-
fects of the treatment, no adverse tissue changes—neither
tumor formation nor calcification at the implantation
site— were recorded in the cardiac CT and MRI studies.
Furthermore, no relevant malignant or sustained ventriculargery c December 2011
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of the stem cell–treated patients, with no statistically signif-
icant changes in the preoperative Lown classification. (2) In
the long-term evaluations of myocardial performance and
volumetric measurements, cardiac function did not deterio-
rate significantly in comparison to the preoperative level
when patients were analyzed irrespective of preoperative
LVEF. Patients who had a moderately to severely compro-
mised LVEF not greater than 40% seemed to gain more
functional benefit from stem cell therapy (improvement of
at least 5% in LVEF) than did patients with a preoperative
LVEF higher than 40%. Only patients with LVEF not more
than 40% had significant improvement in LVEF during the
entire follow-up period. Moreover, patients who were
treated between 7 to 12 weeks after myocardial infarction
seemed to have a significantly higher chance of improve-
ment than did those who were operated on later than 12
weeks after infarction.
The NYHA functional class and MLHFQ scores of our
stem cell–treated patients seem to indicate a similar clinical
course and comparable quality of life to those of the control
group. Statistical analysis for these parameters did not
detect any significant difference, perhaps as a result of the
limited number of patients.
When stem cell and control groups were compared with-
out selection of patients with respect to the preoperative
myocardial function, a significant difference in myocardial
function regarding LVEF could only be determined after 6
months of follow-up. In a subgroup of patients with a preop-
erative LVEF not greater than 40%, only those who under-
went stem cell injection showed significant improvement in
LVEF at 6 months, 18 months, and long-term follow-up,
whereas no significant improvement was seen in the control
group during the follow-up. Moreover, the LVEF and
LVEDD in the stem cell group were significantly better
than in the control group at 6 months. Further, we were
able to show that preoperative LVEF not greater than
40% may be an independent predictor that significantly in-
fluences functional benefit from stem cell treatment beyond
the anticipated LVEF improvement of at least 5% after
CABG. Importantly, the interval between ischemic myocar-
dial injury and the operation with concomitant stem cell
treatment seems to boost the chance of a LVEF improve-
ment of at least 5%, especially if this interval lies between
7 and 12 weeks. Experimental studies suggest cell delivery
beyond the early phase of peak inflammatory response, with
an optimal result around 3 weeks after acute event. Little
guidance can be drawn from clinical studies to date, how-
ever, regarding the optimal timing of cell therapy.21
With cardiac MRI, we found the mean LVEF in the stem
cell group to be higher than that in the control group in
the long-term follow-up. In addition, LVEDV and left
ventricular systolic volume indices in the stem cell group
were also significantly lower than in the control group.The Journal of Thoracic and CarIt is conceivable that the functional benefits in the stem
cell group may have been related to the improved myocar-
dial perfusion score in the infarction area, which was
statistically significant compared to the control group.
The lack of preoperative MRI investigations, however,
prevents drawing conclusions from these statistical results.
Recently, in a short-term study van Ramshorst and associ-
ates22 showed improved myocardial perfusion after stem
cell treatment in patients who were considered ineligible
for myocardial revascularization. Moreover, Klein and
coworkers23 reported, besides in addition to safety, an im-
provement in MRI-determined LVEF and NYHA func-
tional class in all patients with severely depressed left
ventricular function after stand-alone treatment with autol-
ogous CD133þ BMSCs. In patients with only moderately
depressed baseline myocardial function, only regional per-
fusion and regional contractile function were improved 4
months after intramyocardial BMSC transplant during
CABG.24
In a study that used an alternative stem cell delivery route
but also intramyocardial injection, Tse and colleagues25 re-
ported long-term safety results of catheter-based autologous
bone marrow mononuclear stem cell implantation in 12 pa-
tients. In that study, the injected cell number of CD34þstem
cells was considerably lower than that in our own trial.
There was also no tumor or new scar formation, nor was
there calcification at the site of cell implantation. Tse and
colleagues25 did not observe any new-onset ventricular ar-
rhythmias. In these patients, however, LVEF was relatively
normal at 60%  10%, in contrast to a mean preoperative
LVEF of 41.1% 8.1% in our patient population. Further-
more, a significant number of major cardiovascular events
took place, possibly because of the progression of coronary
artery disease in nontargeted regions.
Patel and associates14 demonstrated comparable short-
term results in a randomized study of 20 patients with intra-
myocardial injection of CD34þ autologous BMSCs and
off-pump CABG surgery. A significant improvement in
LVEF as great as 16.7% was observed at 6 months in the
stem cell–treated group, in contrast to 6.5% in the control
group. Furthermore, catheter-based intramyocardial injec-
tions of mononuclear bone marrow cell preparations also
have been reported by Perin and colleagues7 and Fuchs
and associates26 to improve left ventricular function effi-
ciently in chronic ischemic heart disease, partly after longer
follow-up periods.
Some of the transcoronary approaches for infusion of
bone marrow or circulating blood–derived progenitor cells
have been reported to yield functional benefit in patients
with acute myocardial infarction. One-year results of the
TOPCARE-AMI pilot trial4 indicated, in addition to safety
and feasibility, a favorable effect on left ventricular remod-
eling. In the scenario of chronic ischemic heart disease after
myocardial infarction, a controlled, randomized studydiovascular Surgery c Volume 142, Number 6 1537
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in short-term follow-up after intracoronary application of
BMSCs.5
Similarly, Bartunek and colleagues27 showed improved
left ventricular function and increasedmyocardial perfusion
at 4-month follow-up after intracoronary delivery of en-
riched CD133þ progenitor cells. Although they showed
the feasibility of intracoronary injection, the treatment
was associated with an increased incidence of coronary
events in the stem cell group. In contrast, Beitnes and co-
workers28 were able to show safety but no functional benefit
with respect to left ventricular performance in 50 patients
with ST-elevation myocardial infarction 3 years after treat-
ment with intracoronary application of autologous BMSCs
during percutaneous coronary intervention.
In a meta-analysis of BMSC studies, Abdel-Latif and
associates29 reported the safety data of the studies that pre-
dominantly used the intracoronary route for stem cell deliv-
ery with a mean follow-up time of 4 months (range, 3–18
months). There was also a lack of uniformity in the stem
cell type used as well as the lack of a standard indication
for stem cell treatment, such as acute and chronic ischemia.
In this statistical analysis, transplant of BMSCs resulted in
a 3.66% (95% confidence interval, 1.93%–5.40%) in-
crease in LVEF; modest improvements in the scar size
and left ventricular end-systolic volume were also evident.
Furthermore, studies with follow-up duration reaching 18
months have failed to show any improvement in the
LVEF. In a recent meta-analysis, Donndorf and col-
leagues30 included only 6 randomized, controlled studies
of intramyocardial stem cell transplant with CABG in the
setting of chronic myocardial ischemia. They showed sig-
nificant functional benefit, with a mean LVEF improvement
of 5.4% (95% confidence interval, 1.36%–9.44%;
P ¼ .009) after a median follow-up of 6 months, whereas
the incidence of major adverse cardiovascular events did
not show any difference between the treatment arms.
Our analysis, however, has some drawbacks. There was
no randomization of patients in the safety portion of our
trial. Awareness of the study group thus may have affected
the estimates of the NYHA functional class or quality of
life assessments, although similar results were obtained
when stem cell groups in the safety and efficacy trials
were compared. In the controlled, randomized portion, dif-
ficulties were encountered after the first 12 patients because
of the availability of the cell preparation facilities, which
led to a change in our randomization plan (Appendix E2).
We also are not able to provide graft patency data for our
patients, because no follow-up angiography was per-
formed. Even the fact that all patients underwent bypass
grafting to the infarct or peri-infarct zone may have influ-
enced myocardial function. Because of the unplanned with-
drawal of patients, which led to incomplete follow-up
testing of functional assessments, the patient numbers1538 The Journal of Thoracic and Cardiovascular Surwere limited for the final analysis. This fact again may
have caused a lack of significant difference in parameters
despite obvious differences between the groups (eg, in
long-term LVEF improvement). In addition, MLHFQ and
MRI investigations were not available in the preoperative
evaluation, so the results of these examinations should be
accepted with caution.
Overall, we were able to demonstrate only a temporary
and limited efficacy of surgical intramyocardial BMSC
treatment for chronic myocardial ischemia in this small co-
hort. Importantly, wewere able to detect a patient group that
seems to gain the most long-term benefit with respect to the
improvement of LVEFwhen autologous BMSCs are admin-
istered during a CABG procedure. These patients have
a moderate to severe reduction of the LVEF as determined
by preoperative echocardiographic analysis and are oper-
ated on between 7 to 12 weeks after myocardial infarction.
It is of utmost importance for the future of cell-based ther-
apies to identify those patients who might benefit from the
regenerative stem cell effects to define any additional indi-
cations for a concomitant cell-based approach with surgical
myocardial revascularization.
We thank Anne M. Gale and Kara L. Krajewski, MD, for their
editorial assistance. We acknowledge the support of Guenther
K€undt, MD, PhD, from the Institute of Biostatistics and Informat-
ics at the University of Rostock. We thank our study team, espe-
cially Sandra Bubritzki and Petra Paschen, for their great effort
and professional assistance in completing the follow-up investiga-
tions and data collection.References
1. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, et al. Mobilized
bone marrow cells repair the infarcted heart, improving function and survival.
Proc Natl Acad Sci U S A. 2001;98:10344-9.
2. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, et al.
Implantation of bone marrow mononuclear cells into ischemic myocardium en-
hances collateral perfusion and regional function via side supply of angioblasts,
angiogenic ligands, and cytokines. Circulation. 2001;104:1046-52.
3. Anversa P, Kajstura J. Ventricular myocytes are not terminally differentiated in
the adult mammalian heart. Circ Res. 1998;83:1-14.
4. Sch€achinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, et al.
Transplantation of progenitor cells and regeneration enhancement in acute myo-
cardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll
Cardiol. 2004;44:1690-9.
5. Assmus B, Honold J, Sch€achinger V, Britten MB, Fischer-Rasokat U,
Lehmann R, et al. Transcoronary transplantation of progenitor cells after myo-
cardial infarction. N Engl J Med. 2006;355:1222-32.
6. Beltrami AP, Barlucchi L, Torella D, BakerM, Limana F, Chimenti S, et al. Adult
cardiac stem cells are multipotent and support myocardial regeneration. Cell.
2003;114:763-76.
7. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, et al.
Transendocardial, autologous bone marrow cell transplantation for severe,
chronic ischemic heart failure. Circulation. 2003;107:2294-302.
8. Ince H, Petzsch M, Kleine HD, Eckard H, Rehders T, Burska D, et al. Prevention
of left ventricular remodelling with granulocyte colony-stimulating factor after
acute myocardial infarction: final 1-year results of the Front-Integrated Revascu-
larization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by
Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation.
2005;112(9 Suppl):I73-80.
9. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone
marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-5.gery c December 2011
Yerebakan et al Perioperative Management10. Yoon YS, Wecker A, Heyd L, Park JS, Tkebuchava T, Kusano K, et al. Clonally
expanded novel multipotent stem cells from human bone marrow regenerate
myocardium after myocardial infarction. J Clin Invest. 2005;115:326-38.
11. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al.
Neovascularization of ischemic myocardium by human bone-marrow-derived
angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves
cardiac function. Nat Med. 2001;7:430-6.
12. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischemic
myocardium by intramyocardial autologous bone marrow mononuclear cell im-
plantation. Lancet. 2003;361:47-9.
13. Wollert KC, Drexler H. Mesenchymal stem cells for myocardial infarction:
promises and pitfalls. Circulation. 2005;112:151-3.
14. PatelAN,Geffner L,VinaRF, Saslavsky J,UrschelHC Jr, KormosR, et al. Surgical
treatment of congestive heart failure with autologous stem cell transplantation:
a prospective randomized study. J Thorac Cardiovasc Surg. 2005;130:1631-8.
15. Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, et al.
Intramyocardial delivery of CD133þ bone marrow cells and coronary artery
bypass grafting for chronic ischemic heart disease: safety and efficacy studies.
J Thorac Cardiovasc Surg. 2007;133:717-25.
16. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Kllinge H, et al.
Autologous bone marrow stem cell transplantation for myocardial regeneration.
Lancet. 2003;361:45-6.
17. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF
gene delivery to myocardium: deleterious effects of unregulated expression.
Circulation. 2000;102:898-901.
18. Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, et al.
Autologous skeletal myoblast transplantation for severe postinfarction left
ventricular dysfunction. J Am Coll Cardiol. 2003;41:1078-83.
19. Yoon YS, Park JS, Tkebuchava T, Luedeman C, Losordo DW. Unexpected severe
calcification after transplantation of bone marrow cells in acute myocardial
infarction. Circulation. 2004;109:3154-7.
20. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Fail-
ure questionnaire as a measure of therapeutic response to enalapril or placebo.
Am J Cardiol. 1993;71:1106-7.The Journal of Thoracic and Car21. ter Horst KW. Stem cell therapy for myocardial infarction: are we missing time?
Cardiology. 2010;117:1-10.
22. van Ramshorst J, Bax JJ, Beeres SL, Dibbets-Schneider P, Roes SD, Stokkel MP,
et al. Intramyocardial bone marrow cell injection for chronic myocardial ische-
mia: a randomized controlled trial. JAMA. 2009;301:1997-2004.
23. Klein HM, Ghodsizad A, Marktanner R, Poll L, Voelkel T, Mohammad
Hasani MR, et al. Intramyocardial implantation of CD133þ stem cells im-
proved cardiac function without bypass surgery. Heart Surg Forum. 2007;
10:E66-9.
24. Hendrikx M, Hensen K, Clijsters C, Jongen H, Koninckx R, Bijnens E, et al.
Recovery of regional but not global contractile function by the direct intramyo-
cardial autologous bone marrow transplantation: results from a randomized con-
trolled clinical trial. Circulation. 2006;114(1 Suppl):I101-7.
25. Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, et al.
Safety of catheter-based intramyocardial autologous bone marrow cells implan-
tation for therapeutic angiogenesis. Am J Cardiol. 2006;98:60-2.
26. Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R, et al. Cath-
eter-based autologous bone marrow myocardial injection in no-option patients
with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol.
2003;41:1721-4.
27. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B,
De Bondt P, et al. Intracoronary injection of CD133-positive enriched bone
marrow progenitor cells promotes cardiac recovery after recent myocardial
infarction: feasibility and safety. Circulation. 2005;112(9 Suppl):I178-83.
28. Beitnes JO, Hopp E, Lunde K, Solheim S, Arnesen H, Brinchmann JE, et al.
Long-term results after intracoronary injection of autologous mononuclear
bone marrow cells in acute myocardial infarction: the ASTAMI randomised,
controlled study. Heart. 2009;95:1983-9.
29. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, et al.
Adult bone marrow-derived cells for cardiac repair: a systematic review and
meta-analysis. Arch Intern Med. 2007;167:989-97.
30. Donndorf P, Kundt G, Kaminski A, Yerebakan C, Liebold A, Steinhoff G, Glass
A. Intramyocardial bone marrow stem cell transplantation during coronary artery
bypass surgery: a meta-analysis. J Thorac Cardiovasc Surg. Epub 2011Mar 2.diovascular Surgery c Volume 142, Number 6 1539
P
M
APPENDIX E1. PATIENT RANDOMIZATION
For the prospective, controlled study arm (efficacy study),
a randomization plan was generated with an open-access
web-based tool (http://www.tufts.edu/gdallal/PLAN.
HTM) based on 100 subjects and 5 subblocks. This plan
was followed for the first 12 patients. Because of the limited
availability of the hematology class B procedure room, pur-
suing the trial became increasingly more difficult. The strat-
ification strategy was therefore modified: Patients whowere
operated on during a week when the procedure room was
available were allocated to the treatment group. When the
hematology class B clean room was not available, the pa-
tient was stratified to the control group. Availability of the
clean room was beyond the control of the investigators, re-
sulting in the following random allocation sequence:
0100001100111001000101010100101011110111, where
0 represents coronary artery bypass grafting only and 1 rep-
resents coronary artery bypass grafting with cell injection.
Patients, surgeons, and physicians were blinded to the study
group in the in the prospective, controlled study arm.
APPENDIX E2. SURGICAL PROCEDURE
All patients were operated on under conditions of cardio-
pulmonary bypass and cardioplegic arrest. The left internal
thoracic artery was used routinely, and saphenous vein
grafts or radial artery grafts were harvested as needed.
All coronary arteries with relevant stenosis and sufficient
diameter were grafted. All patients received the same cardi-
oplegic solution. Once the coronary artery anastomoses had
been completed, the infarct area was visualized and 10 0.2-
mL aliquots of cell suspension were injected in the infarct
border zone whenever this could be clearly visualized.
Otherwise, cells were injected in an area of myocardium
that corresponded to the localization of the perfusion defect
on scintigraphy and disturbed wall motion on echocardiog-
raphy and left ventricular angiography. A swab was used to
occlude the injection channel for several seconds to mini-
mize reflux of cell suspension. Immediately after the cell
injection, the aortic clamp was removed, and the operation
was completed as usual. In the control group of patients un-
dergoing coronary artery bypass grafting alone, no sham in-
jection was performed. After the stay in the intensive care
unit and intermediate care unit, patients recovered on the
surgical ward for at least 12 days, or they were transferred
to the referring cardiology unit earlier. Standard postopera-
tive medication included aspirin (INN acetylsalicylic
acid, 100 mg daily), b-blockers, statins, and angiotensin-
converting enzyme inhibitors and was adjusted by the
cardiologist caring for the patient during follow-up as
needed.
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FIGURE E1. Representative single-photon emission computed tomographic scans of a patient from the stem cell group who underwent bypass grafting to
the left anterior descending, circumflex, and right coronary arteries, as well as the injection of 6 3 106 CD133-selected CD34þcells in the posteroinferior
area of myocardial infarction. At discharge (2 weeks), tracer activity in the infarct area was still diminished; however, perfusion had virtually returned to
normal at 3 months and showed sustained superior perfusion at 3 years relative to preoperative activity in the area of stem cell injection.
TABLE E1. Numbers of patients who had undergone follow-up investigations for each investigation and time point
Preoperative 3 mo 6 mo 12 mo 18 mo 36 mo
Long-term
follow-up
MLHFQ SC 26, Control 14
New York Heart Association class All patients NP NP NP SC 34, Control 13
Transthoracic echocardiography All patients SC 20, Control 15 SC 20, Control 15 SC 20, Control 15
Myocardial perfusion scan SC 24, Control 11 SC 24, Control 11
Holter All patients NP NP NP SC 20, Control 15
Magnetic resonance imaging SC 18, Control 7
Computed tomography SC 15, Control 7
MLHFQ,Minnesota Living With Heart Failure Questionnaire; SC, stem cell group; NP, not presented (follow-up investigation was performed but is not presented in this article).
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TABLE E2. Factors included in the univariate and multivariate regression analyses
Parameter
Univariate logistic regression Multivariate logistic regression
P value Unadjusted OR 95% CI P value Adjusted OR 95% CI
Therapy
Treatment vs control .589 0.679 0.167–2.77
Age
>60 vs 60 y .384 1.86 0.461–7.48
Sex
Female vs male .317 3.25 0.323–32.8
Postinfarct time (wk)
6 vs>12 .208 3.60 0.491–26.4 .307 4.34 0.260–72.3
7–12 vs>12 .029 12.0 1.29–111 .023 56.4 1.75–1812
New York Heart Association functional class
2 vs 3 .819 0.750 0.064–8.83
2.5 vs 3 .860 1.17 0.210–6.48
Bypass grafts
 4 vs 3 .168 2.70 0.657–11.1 .858 0.791 0.061–10.3
Preoperative left ventricular end-diastolic diameter (mm)
55–60 vs 55 .951 0.952 0.200–4.54
>60 vs 55 .852 1.19 0.190–7.46
Preoperative left ventricular end-diastolic volume (mL)
141-170 vs 140 .141 0.268 0.046–1.55
>170 vs 140 .876 0.857 0.124–5.94
Preoperative left ventricular ejection fraction
40% vs>40% .004 14.0 2.37–82.7 .018 43.9 1.92–1006
OR, Odds ratio; CI, confidence interval.
TABLE E3. Comparison of left ventricular ejection fraction between stem cell and control groups in subgroups of patients with preoperative left
ventricular ejection fraction not greater than 40% and greater than 40% and in subgroups of patients who were treated between 7 and 12 weeks
after infarction and treated beyond 12 weeks after infarction
Preoperative 6 mo 18 mo Long-term
Preoperative LVEF 40
Control 32.6%  9.7% 37.6%  6.9% 46.0%  7.7% 39.3%  14.0%
Stem cell 33.0%  5.4% 50.6%  9.4% 45.6%  11.8% 52.1%  14.8%
Preoperative LVEF>40
Control 47.5%  3.7% 49.5%  3.0% 47.6%  4.5% 52.1%  6.9%
Stem cell 47.2%  3.8% 49.3%  7.1% 45.5%  9.7% 42.6%  8.5%
Treated 7–12 wk after myocardial infarction
Control 40.5%  7.4% 44.3%  6.4% 53.0%  2.8% 46.8%  8.0%
Stem cell 41.9%  8.8% 49.5%  6.7% 49.4%  7.6% 52.5%  8.8%
Treated beyond 12 wk after myocardial infarction
Control 43.6%  6.5% 44.6%  7.4% 42.0%  8.2% 42.2%  18.7%
Stem cell 43.5%  7.3% 53.5%  3.4% 50.3%  7.1% 44.0%  13.8%
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